About Lifeward products
Lifeward offers medical devices for rehabilitation and recovery.
golifeward.comCrawled Nov 13, 2026
Lifeward offers medical devices for rehabilitation and recovery.
Lifeward shares advancements in neurological therapy using robotics through articles and resources.
Robotics in physical therapy improves patient outcomes, as demonstrated by clinician use.
Lifeward strives to serve veterans with spinal cord injury. ReWalk Personal is theraputic robotic technology that saves lives.
ReWalk Robotics welcomes a Medicare proposal to classify personal exoskeletons as a lump-sum benefit category.
Find resources from Lifeward on technological advances in neuro physical therapy.
ReWalk’s stair and curb capability earns FDA clearance as the only personal exoskeleton for paralyzed individuals with spinal cord injuries.
Lifeward Ltd. provides life-changing rehabilitation and recovery solutions globally.
Lifeward completed its rebranding and formal name change in Israel after shareholder and registrar approval.
The U.S. Department of Veterans Affairs evaluates, trains, and procures ReWalk Personal exoskeleton systems for qualifying veterans nationwide.
Lifeward medical devices have varying pricing based on insurance and other factors; a reimbursement team assists with inquiries.
The ReWalk Personal Exoskeleton is covered under Medicare’s brace benefit category as of January 1, 2024, if deemed reasonable and necessary.
Lifeward is a medical device company that designs and develops powered solutions that provide gait training and mobility for lower limb disabilities.
Lifeward expands insurance coverage for its ReWalk Personal Exoskeleton to include Aetna, joining Humana and United Healthcare. These three insurers now cover the device for Medicare Advantage beneficiaries who meet medical necessity criteria, collectively serving around 16 million enrollees nationwide.
Lifeward Ltd. partners with Oramed Pharmaceuticals to form a diversified biomedical innovation company. The collaboration positions Lifeward as a MedTech platform targeting cashflow positivity while pursuing long-term biotech growth potential. The agreement integrates Oramed’s drug delivery technologies into Lifeward’s portfolio, expanding its focus on diabetes and metabolic disease treatments.
Lifeward Ltd. secures payment from the first commercial Medicare Advantage plan for its ReWalk 7 personal exoskeleton. The company reports accelerated claim approval timelines, with a Medicare Advantage claim processed in under 30 days and progress on traditional Medicare claims in 2025. This marks a key step in expanding reimbursement access for the wearable mobility device.
Lifeward secures CE Mark approval for its seventh-generation ReWalk 7 exoskeleton, enabling commercial sales in the European Union. The device supports mobility for users with lower-limb paralysis. Lifeward, a Nasdaq-listed company, develops wearable robotic solutions for rehabilitation and mobility assistance.
An Administrative Law Judge rules that the ReWalk Personal Exoskeleton qualifies as a **reasonable and necessary** medical device under Medicare coverage. The decision allows paralyzed individuals to access the exoskeleton for standing and walking in daily life. ReWalk, developed by Israeli company ReWalk Robotics, enables mobility for users with paralysis.